HDL-C Above 80 mg/dL Is Killing the Men It Clears
The Marker and the Market
Money is moving into biomarker precision: HDL-C panels, comprehensive lipid workups, metabolic scores that promise to find hidden cardiovascular risk in patients who feel perfectly well. The clinical picture, as of June 27, is considerably less reassuring. Peter Attia's analysis, drawing on UK Biobank data and a meta-analysis of more than one million individuals, documents a U-shaped mortality curve above an HDL-C of roughly 80 mg/dL, with the excess risk concentrated in men. A cohort running a median HDL-C of 98 mg/dL, the kind of reading a longevity clinic would mark green, showed approximately half with detectable coronary artery calcium (a measure of plaque buildup in the arteries, scored by CT scan and one of the stronger predictors of cardiac events); in that group, coronary artery calcium predicted all-cause mortality more strongly than traditional risk factors. Capital is treating elevated HDL-C as cardiovascular protection. The trial record delivers the opposite: no drug that raises HDL-C has produced cardiovascular benefit. Niacin trials, fibrate trials, torcetrapib, and CETP inhibitors, a class of drugs designed specifically to raise HDL-C, all failed to help hearts, despite hitting their pharmacological targets. SCARB1 variants that elevate HDL-C are associated with paradoxically higher cardiovascular risk. A longevity clinic operator who in 2024 reassured a 50-year-old male patient based on an HDL-C of 98, while dismissing his coronary calcium score, is standing on documented ground that has already given way: the pharmacological case closed with torcetrapib in 2006, the genetic case closed with SCARB1, and the population case closed with the UK Biobank cohort published June 27.
Capital Ahead of the Protocol
74 billion dollars, running 56 percent ahead of Q1 2025, with the full-year projection at 8 to 9 billion dollars. 4 million dollars, about 2 percent of capital deployed. 1 billion dollars; its first human trial targets alcohol-related liver disease, a real endpoint on a real patient population rather than a longevity concept priced on an IND (an investigational new drug application, the regulatory submission that clears a therapy to enter human trials). That is the right direction: a 1 billion dollar valuation built on a liver disease trial. The science being imported into APAC longevity clinics is still priced on HDL-C panels the pharmacological record stopped supporting when torcetrapib failed in 2006. The APAC-LMIS summit, scheduled October 1-4 in Hong Kong under the Asia-Pacific Longevity Medicine Society and the Kitalys Institute, is positioning the city as a translational hub for longevity medicine capital and regulatory science. The convening matters. The risk is that it gathers capital and clinic operators around a biomarker suite that the underlying science has been quietly dismantling for a decade. China's NMPA (the National Medical Products Administration, equivalent to the FDA for drugs and medical devices) issued a November 2025 cosmetics reform requiring substantiated anti-aging efficacy claims for ingredient filings; filings rose more than 40 percent between 2024 and 2025, which means the compliance burden now falls on a fast-growing stack of products. The October 1-4 summit in Hong Kong has the room to put that question directly to clinic operators and the family offices funding the rollouts. The NMPA already has.
The family offices funding clinic rollouts across Singapore, Hong Kong, and Bangkok are running HDL-C panels on a pharmacological record that closed in 2006. The UK Biobank data is public. The CAC scoring protocol is available at any accredited imaging center. The October summit runs four days in Hong Kong; the agenda is not yet published. If HDL-C appears as a cardiovascular clearance marker without a CAC co-requirement, the liability question will be on the table whether the program addresses it or not.